BeyondSpring Inc. — FY2018 Form 20-F
Reporting period: Fiscal year ended December 31, 2018. This is an annual report, not a standalone fourth-quarter filing. Financial statements are prepared under U.S. GAAP; amounts below are in U.S. dollars unless noted.
Business context
BeyondSpring is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its lead candidate, Plinabulin, is being studied for non-small cell lung cancer (NSCLC) and chemotherapy-induced neutropenia (CIN); additional immuno-oncology programs remain preclinical or early-stage. The company owns Plinabulin rights globally except in China, where its subsidiary is 60%-owned by BeyondSpring.
Financial results and liquidity
| Metric | FY2018 / Dec. 31, 2018 | Comparable period / Dec. 31, 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $51.6 million | $88.9 million |
| General and administrative expense | $5.9 million | $9.1 million |
| Operating loss | $57.5 million | $98.0 million |
| Net loss | $57.5 million; $2.42 per share | $96.4 million; $4.40 per share |
| Cash used in operating activities | $40.0 million | $28.8 million |
| Cash and short-term investments | $3.9 million | $30.6 million |
| Total assets | $7.1 million | $32.8 million |
| Current liabilities / total liabilities | $16.4 million | $4.8 million |
| Total equity (deficit) | $(9.4) million | $28.0 million |
| Accumulated deficit | $178.8 million | $123.9 million |
There is no meaningful gross margin because the company had no revenue. The filing reports no income-tax benefit. No debt is reported on the December 31, 2018 balance sheet; the reported liabilities are current liabilities. The company reported negative working capital and its auditor highlighted substantial doubt about its ability to continue as a going concern.
Material changes and unusual items
- Net loss narrowed by approximately 40% year over year, but operating cash use increased by $11.2 million to $40.0 million.
- 2017 R&D included a $42.3 million noncash charge for 2,112,963 shares issued to Nereus Trust to terminate royalty arrangements. Excluding that item, R&D expense rose from $46.6 million in 2017 to $51.6 million in 2018, principally due to higher clinical-trial and manufacturing costs, partly offset by lower share-based compensation.
- Cash fell by $23.6 million during 2018. The company raised $14.0 million net from its May 2018 share issuance; the related agreements contemplated $20.0 million in gross proceeds, but the company said it did not expect to receive the remaining $6.0 million in the near future.
- 2018 other income included a $315,000 government grant previously recorded as a liability; local approval to recognize it was obtained in January 2018. Foreign exchange shifted from a $555,000 gain in 2017 to a $455,000 loss in 2018.
- Lease commitments totaled $4.0 million, including $792,000 due within one year. The filing says the company planned to adopt the new lease accounting standard in 2019.
Outlook, clinical updates and risks
- Management expects continued significant losses and negative cash flows and says additional financing is needed. Funding options include equity or debt, licensing and partnerships; availability and acceptable terms are not assured, and equity financing could dilute shareholders. The auditor’s going-concern paragraph reflects this risk.
- Study 105’s Phase 3 portion met its primary endpoint of non-inferiority to Neulasta for first-cycle duration of severe neutropenia in a prespecified interim analysis, according to the company. Study 106’s Phase 2 results were described as favorable; its Phase 3 portion had not yet begun.
- Study 103, a 554-patient Phase 3 NSCLC trial, had enrolled more than 400 patients. The first interim review recommended continuation; a second interim analysis was expected in Q4 2019, with final results expected in 2020 if the trial continued. Earlier Study 101 did not meet its primary overall-survival endpoint in the full population; the reported measurable-lesion subgroup analysis was small and not statistically significant.
- Management planned to seek Chinese NDAs for NSCLC and CIN in 2019, potentially through conditional or accelerated pathways, and U.S. NDAs in 2020 if trial results supported filings. These were plans, not approvals or guaranteed timelines; relevant Chinese guidance and eligibility remained uncertain.
- Key risks include clinical efficacy or safety failures, regulatory delays or additional-study requirements, reliance on external trial and manufacturing vendors, financing needs, competition, reimbursement uncertainty, and intellectual-property protection. BASF was the sole supplier of Solutol, a stabilizer in the current formulation; a supply disruption could require reformulation.
- After year-end, the company disclosed loans including a RMB 20 million facility at 15% interest (RMB 10 million drawn by the report date, with maturity later extended), a RMB 10 million bank loan at 5.7%, and a $1 million loan at 15%. It was also repaid in April 2019 for a $481,000 interest-free 2018 loan to its Chief Medical Officer; the filing states the loan may have violated Exchange Act Section 13(k).
- Management reported effective disclosure controls and internal control over financial reporting at year-end. A prior material weakness in financial-reporting staffing was reported as remediated by December 31, 2017. The auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Current cash, actual cash burn, and the timing and terms of additional financing; reconcile reported year-end liquidity with subsequent borrowing and any later proceeds.
- Whether the remaining $6.0 million from the May 2018 share financing was ever received, and the resulting dilution from any subsequent equity issuance.
- Final, independently reported Study 103, 105 and 106 results, including endpoints, statistical significance, safety, patient populations and regulatory acceptance.
- Whether Chinese conditional-approval eligibility and U.S. filing requirements were confirmed by regulators, and whether the stated 2019–2020 filing plans were achieved.
- The nature and resolution of the Section 13(k) matter, and any related regulatory or governance consequences.
- The financial statements report FY2018 net loss of $57.474 million, while some liquidity discussion cites $56.9 million; confirm the audited financial-statement figure when comparing disclosures.